Company IntelliPharmaCeutics International Inc. OTC Bulletin Board
Equities
CA4581733090
Pharmaceuticals
Business Summary
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Licensing
45.2
%
| - | - | 0 | 45.2 % | - |
Up-front Fees
29.0
%
| - | - | 0 | 29.0 % | - |
Other Services
25.8
%
| - | - | 0 | 25.8 % | - |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
45.2
%
| - | - | 0 | 45.2 % | - |
Canada
29.0
%
| 0 | nan % | 0 | 29.0 % | - |
Other
25.8
%
| - | - | 0 | 25.8 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Amina Odidi
FOU | Founder | - | 01/98/01 |
Isa Odidi
CEO | Chief Executive Officer | - | 01/98/01 |
Comptroller/Controller/Auditor | - | 01/07/01 | |
Corporate Officer/Principal | - | 01/14/01 | |
Patrick Yat
PRN | Corporate Officer/Principal | - | 01/92/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Norman Betts
BRD | Director/Board Member | 69 | 22/19/22 |
Isa Odidi
CEO | Chief Executive Officer | - | 01/98/01 |
Amina Odidi
FOU | Founder | - | 01/98/01 |
Bahadur Madhani
BRD | Director/Board Member | - | 01/06/01 |
Shawn Graham
BRD | Director/Board Member | - | 01/18/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 33,092,665 | 32,511,067 ( 98.24 %) | 0 | 98.24 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GROWLIFE, INC. 10.84% | 3,662,761 | 10.84% | 7,326 $ |
Company contact information
Intellipharmaceutics International, Inc.
30 Worcester Road
M9W 5X2, Toronto
+416 798 3001
http://www.intellipharmaceutics.com![address IntelliPharmaCeutics International Inc.](https://cdn.zonebourse.com/static/address/58320058.png)
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+52.93% | 803B | |
+41.20% | 631B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.77% | 243B | |
+2.13% | 228B | |
+10.19% | 217B | |
+6.24% | 164B |